Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.


Journal

Annals of emergency medicine
ISSN: 1097-6760
Titre abrégé: Ann Emerg Med
Pays: United States
ID NLM: 8002646

Informations de publication

Date de publication:
01 2020
Historique:
received: 11 01 2019
revised: 12 07 2019
accepted: 19 07 2019
pubmed: 9 10 2019
medline: 25 4 2020
entrez: 9 10 2019
Statut: ppublish

Résumé

Nonfatal opioid overdose represents an opportunity to engage young adults into using medication for opioid use disorder. We seek to describe characteristics of young adults who experience nonfatal overdose and estimate rates of and time to medication for opioid use disorder for young adults relative to those aged 26 to 45 years. We conducted a cohort study using retrospective administrative data of 15,281 individuals aged 18 to 45 years who survived an opioid-related overdose in Massachusetts between 2012 and 2014, using deidentified, individual-level, linked data sets from Massachusetts government agencies. We described patient characteristics stratified by age (18 to 21, 22 to 25, and 26 to 45 years) and evaluated multivariable Cox proportional hazards models to compare rates of medication for opioid use disorder receipt, controlling for age, sex, history of mental health disorders, and addiction treatment. Among 4,268 young adults in the year after nonfatal overdose, 28% (n=336/1,209) of those aged 18 to 21, 36% (n=1,097/3,059) of those aged 22 to 25 years, and 36% (n=3,916/11,013) of those aged 26 to 45 years received medication for opioid use disorder. For individuals aged 18 to 21 and 22 to 25 years, median time to buprenorphine treatment was 4 months (interquartile range 1.7 to 1.8 months); to methadone treatment, 4 months (interquartile range 2.8 to 2.9 months); and to naltrexone treatment, 1 month (interquartile range 1 to 1 month). Individuals aged 18 to 21 years were less likely (adjusted hazard ratio 0.60 [95% confidence interval 0.45 to 0.70]) to receive methadone than those aged 22 to 25 and 26 to 45 years. Individuals aged 18 to 21 years and those aged 22 to 25 years were more likely to receive naltrexone (adjusted hazard ratio 1.65 [95% confidence interval 1.36 to 2.00] and 1.41 [95% confidence interval 1.23 to 1.61], respectively) than those aged 26 to 45 years. One in 3 young adults received medication for opioid use disorder in the 12 months after surviving an overdose. Type of medication for opioid use disorder received appeared to be age associated. Future research should focus on how medication choice is made and how to optimize the emergency department for medication for opioid use disorder initiation after nonfatal overdose.

Identifiants

pubmed: 31591014
pii: S0196-0644(19)30616-X
doi: 10.1016/j.annemergmed.2019.07.030
pmc: PMC7953238
mid: NIHMS1675702
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Buprenorphine 40D3SCR4GZ
Naltrexone 5S6W795CQM
Methadone UC6VBE7V1Z

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-38

Subventions

Organisme : NIDA NIH HHS
ID : K23 DA044324
Pays : United States
Organisme : NIDA NIH HHS
ID : L30 DA044647
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Références

Addiction. 2004 Jan;99(1):39-52
pubmed: 14678061
JAMA. 2014 Apr 9;311(14):1393-4
pubmed: 24577059
BMJ. 2012 Oct 03;345:e5945
pubmed: 23038795
Ann Emerg Med. 2018 Jun;71(6):688-690
pubmed: 29523371
J Addict Med. 2014 May-Jun;8(3):176-82
pubmed: 24695018
Ann Pharmacother. 2009 Mar;43(3):413-22
pubmed: 19261962
Pharmacoepidemiol Drug Saf. 2017 May;26(5):509-517
pubmed: 28074520
J Stud Alcohol. 2003 Jul;64(4):520-30
pubmed: 12921194
J Gen Intern Med. 2017 Jun;32(6):660-666
pubmed: 28194688
Eval Health Prof. 2014 Jun;37(2):147-55
pubmed: 24492245
MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):719-25
pubmed: 26158353
Addict Behav. 2017 Feb;65:229-235
pubmed: 27561431
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
MMWR Morb Mortal Wkly Rep. 2018 Mar 09;67(9):279-285
pubmed: 29518069
JAMA. 2015 Apr 28;313(16):1636-44
pubmed: 25919527
JAMA Psychiatry. 2017 May 1;74(5):445-455
pubmed: 28355458
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516

Auteurs

Sarah M Bagley (SM)

Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA. Electronic address: https://twitter.com/sbagley@bu.edu.

Marc R Larochelle (MR)

Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA.

Ziming Xuan (Z)

Department of Community Health Sciences, Boston University School of Public Health, Boston, MA.

Na Wang (N)

Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA.

Aneesh Patel (A)

Boston University School of Medicine, Boston, MA.

Dana Bernson (D)

Massachusetts Department of Public Health, Boston, MA.

Michael Silverstein (M)

Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA.

Scott E Hadland (SE)

Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA.

Thomas Land (T)

University of Massachusetts, Worcester, MA.

Jeffrey H Samet (JH)

Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA; Department of Community Health Sciences, Boston University School of Public Health, Boston, MA.

Alexander Y Walley (AY)

Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA; Massachusetts Department of Public Health, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH